Lv11
10 积分 2021-09-27 加入
Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis
3小时前
已完结
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
5天前
已完结
Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial
25天前
已完结
Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer
28天前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
28天前
已完结
Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer
1个月前
已完结
KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy
1个月前
已完结
The pancreatic cancer drug market
1个月前
已完结
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
2个月前
已完结
ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours
2个月前
已完结
皖公网安备34019202002308
